Clinical Trials Logo

Everolimus clinical trials

View clinical trials related to Everolimus.

Filter by:
  • None
  • Page 1

NCT ID: NCT05054166 Completed - Breast Cancer Clinical Trials

Efficacy of Everolimus-containing Chemotherapy in HER2- mBC Patients With PI3K/AKT/mTOR Mutations Study

Start date: May 1, 2021
Phase:
Study type: Observational

The study aimed to investigate the efficacy of the everolimus-containing chemotherapy in metastatic breast cancer patients with PI3K/AKT/mTOR mutations.14 cases of HER2- metastatic breast cancer patients with PI3K/AKT/mTOR mutations treated with everolimus-containing chemotherapy were retrospectively analyzed.The genetic profile in PI3K/AKT/mTOR pathway was studied.

NCT ID: NCT03730428 Completed - Pneumonitis Clinical Trials

Everolimus Related Pneumonitis in MBC

Start date: July 15, 2017
Phase:
Study type: Observational

To study the drug-related pneumonitis during mTOR inhibitor therapy in patients with metastatic breast cancer.

NCT ID: NCT03014297 Terminated - Clinical trials for Neuroendocrine Tumors

Fosbretabulin With Everolimus in Neuroendocrine Tumors With Progression

Start date: March 6, 2017
Phase: Phase 1
Study type: Interventional

This is a single center, open label, phase I study involving grade I-III gastroenteropancreatic neuroendocrine tumors, consisting of a dose escalation Part A followed by an expansion cohort Part B. On Part A Patients will be treated with daily oral everolimus. Fosbretabulin will be administered IV either q3 weekly or q weekly based on PO CRM cohort. Part B: Once the investigators have established an MTD in Part A, the investigators will be treating 15 more patients at that dose combination. The primary and secondary objectives of the expansion cohort will be similar to Part A of the study, i.e., to establish a safety profile of the experimental drug combination and to collect and assess efficacy data. Patients will be treated with concurrent everolimus and fosbretabulin for 12 weeks.

NCT ID: NCT01023542 Recruiting - Clinical trials for Liver Transplantation

CNI-free "Bottom"-up Immunosuppression in Patients Undergoing Liver Transplantation

BUILT_01
Start date: June 2011
Phase: Phase 2/Phase 3
Study type: Interventional

The primary objective of the trial is to evaluate efficacy and safety of delayed introduction (up to 30 days post-transplantation in patients without signs of acute rejection that had received an aIL-2 induction and MMF) of either cyclosporine or everolimus versus a 5-day delay of cyclosporine in combination with MMF.

NCT ID: NCT00180453 Completed - Clinical trials for Coronary Artery Disease

SPIRIT FIRST Clinical Trial of the Abbott Vascular XIENCE V® Everolimus Eluting Coronary Stent System

Start date: December 2003
Phase: Phase 3
Study type: Interventional

Prospective, randomized, controlled, single-blinded, parallel two-arm, multicenter trial. Test arm: XIENCE V® Everolimus Eluting Coronary Stent System(stent length: 18mm, diameter: 3.0mm) Control arm: Metallic stent (MULTI-LINK VISION® metallic stent(stent length: 18mm, diameter: 3.0mm) Follow-up angiographic imaging and intra vascular ultra sound (IVUS) at 180 days and 1 year